论文部分内容阅读
【目的】检测人体肝癌组织及癌旁肝组织中表皮生长因子受体EGFR及其突变体EGFRvⅢ的表达情况,并分析其临床意义。【方法】用免疫组化法检测58例肝细胞癌患者肿瘤及癌旁肝组织中EGFR、EGFRvⅢ的表达情况,与患者的临床资料进行相关分析,同时对EGFR和EGFRvⅢ不同表达的患者无瘤生存期和总生存期进行生存分析。【结果】肝癌组织EGFR、EGFRvⅢ表达的阳性率分别为74.1%、63.8%;癌旁肝组织EGFR、EGFRvⅢ表达阳性率分别为81.0%、77.6%。肝癌组织EGFRvⅢ的表达情况与肿瘤病理分级(P=0.028)及术前AFP值(P=0.035)呈负相关。癌栓及/或卫星灶(P<0.001)和肿瘤病理分级(P=0.023)是肝癌术后无瘤生存期的主要影响因素;肝癌患者术后总生存期的主要影响因素包括患者的肿瘤家族史(P=0.014)、肿瘤最大径(P<0.001)、癌栓及/或卫星灶(P=0.039)以及肿瘤的病理分级(P=0.002)。生存分析显示肝癌组织EGFR及EGFRvⅢ表达阴性的患者与表达阳性的患者无瘤生存率及总生存率均无明显差异。【结论】肝细胞癌患者肿瘤组织及癌旁肝组织中均存在EGFR以及EGFRvⅢ高表达,EGFR以及EGFRvⅢ过度表达可能是肝癌发生过程中的事件。肝癌组织EGFRvⅢ的表达情况与肿瘤病理分级及术前AFP值呈负相关,肝癌组织EGFR及EGFRvⅢ的表达情况不是肝癌预后的独立影响因素。
【Objective】 To detect the expression of epidermal growth factor receptor EGFR and its mutant EGFRv Ⅲ in human hepatocellular carcinoma and adjacent liver tissues and to analyze its clinical significance. 【Methods】 The expressions of EGFR and EGFRvⅢ in 58 cases of hepatocellular carcinoma were detected by immunohistochemistry and correlated with the clinical data of the patients. Meanwhile, the patients with different expression of EGFR and EGFRvⅢ had no tumor-surviving Survival analysis of stage and overall survival. 【Results】 The positive rates of EGFR and EGFRvⅢ expression in hepatocellular carcinoma were 74.1% and 63.8%, respectively. The positive rates of EGFR and EGFRv Ⅲ expression in hepatocellular carcinoma tissues were 81.0% and 77.6%, respectively. The expression of EGFRv Ⅲ in HCC tissues was negatively correlated with tumor pathological grade (P = 0.028) and preoperative AFP value (P = 0.035). (P <0.001) and tumor pathological grade (P = 0.023) were the main factors affecting the postoperative tumor-free survival of hepatocellular carcinoma. The main factors influencing the total postoperative survival of patients with hepatocellular carcinoma include the tumor family (P = 0.014), tumor maximum diameter (P <0.001), tumor thrombus and / or satellite (P = 0.039) and tumor grade (P = 0.002). Survival analysis showed no significant difference in tumor-free survival rate and overall survival between patients with negative EGFR and EGFRvIII expression and those with positive expression. 【Conclusions】 Both EGFR and EGFRv Ⅲ are highly expressed in both tumor tissues and adjacent liver tissues of patients with hepatocellular carcinoma. Overexpression of EGFR and EGFRv Ⅲ may be an event in the development of hepatocellular carcinoma. The expression of EGFRvⅢ in hepatocellular carcinoma was negatively correlated with tumor grade and preoperative AFP value. The expression of EGFR and EGFRvⅢ in hepatocellular carcinoma was not independent prognostic factor for hepatocellular carcinoma.